Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02177513 · ClinicalTrials.gov registry record · Phase 1
Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02177513: Completed Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT02177513 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02177513, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Background: \- Marijuana (cannabis) is an illegal drug. Researchers want to study people s reactions, attention, and behavior after they take marijuana in different ways. They want to learn better ways to detect drugs in a person s body They also want to know how long marijuana can be found in blood, urine, saliva, and breath. Objectives: \- To learn how people respond to delta-9-tetrahydrocannabinol (THC, a marijuana component) and how their bodies handle it after it is given in different ways. Eligibility: \- Adults age 18 50 who use marijuana. Design: * Participants are screened under another NIDA protocol. * This study involves up to 6 visits to NIDA. * At the first visit, participants will practice the tasks and tests they will do at their dosing sessions. They will learn how to give breath and saliva samples. * Dosing sessions 1 4 will last 3 5 days each. All participants will be admitted to a research clinic the night before these sessions. Some participants can stay at the clinic and some must go home between sessions. * At each session, participants will eat a brownie with placebo or marijuana. Then they will smoke a placebo or marijuana cigarette. Some will inhale placebo or marijuana after it is vaporized. * Throughout the sessions: * Participants will give urine, saliva, and breath samples. Their blood will be taken with a tube in a vein and finger pricks. Their vital signs will be checked. * Participants will answer questionnaires and take thinking tests. They will also take tests that assess eye movement, balance, and time estimation. * Participants may have a 5th dosing session. They will eat a marijuana brownie and have the above tests and samples.
Interventions
- DRUG Placebo + Placebo
- DRUG Oral Cannabis + Placebo
- DRUG Placebo + Inhaled Cannabis
- DRUG Placebo + Smoked Cannabis
- DRUG 6.9% cannabis oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-06-14 |
| Est. Completion | 2016-04-27 |
| Phase | Phase 1 |
What the finished NCT02177513 record still lists
NCT02177513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo + Placebo is the first listed.
NCT02177513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02177513 about?
NCT02177513 is a clinical study titled "Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics". Background: \- Marijuana (cannabis) is an illegal drug. Researchers want to study people s reactions, attention, and behavior after they take marijuana in different ways. They want to learn better ways to detect drugs in a person s body They also want to know how long marijuana can be found in bloo...
What is the current status of trial NCT02177513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2014-06-14. Estimated completion is 2016-04-27.
What interventions are being tested in trial NCT02177513?
The interventions under investigation include: Placebo + Placebo (DRUG), Oral Cannabis + Placebo (DRUG), Placebo + Inhaled Cannabis (DRUG), Placebo + Smoked Cannabis (DRUG), 6.9% cannabis oral (DRUG).
Who is sponsoring clinical trial NCT02177513?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02177513's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI